The agreement of the OMERACT grey-scale ultrasound scoring system for salivary glands and minor salivary gland biopsy results in a single-center cohort of patients with suspected Sjögren’s disease
Skeletal Radiology · 2025
DOI: 10.1007/s00256-025-04885-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Skeletal Radiology, 2025. Verfasst von Nanna Surlemont Schmidt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet, Copenhagen, Denmark. nanna.s.schmidt…. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Salivary Glands, Salivary Glands, Minor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Hospital.
Abstract (Originalsprache)
Objective
Salivary gland ultrasound (SGUS) is a non-invasive tool for the evaluation of parenchymal changes related to primary Sjögrens disease (pSjD) with the potential to reduce the need for minor salivary gland biopsies when diagnosing patients with pSjD. The aim was to assess the agreement between SGUS findings and minor salivary gland biopsy results in patients suspected of pSjD.
Methods
All patients referred with a suspicion of pSjD and scheduled for a diagnostic minor salivary gland biopsy were included in the period 2017–2021. All underwent SGUS of the parotid and submandibular glands bilaterally, Schirmer’s test, unstimulated salivary flow, and blood samples including autoantibody analysis. Changes in the four glands were scored 0–3 using a previously developed ultrasound atlas based on the OMERACT SGUS scoring system for pSjD. All biopsies were scored at the same pathology department and a focus score > 1 was indicative of pSjD.
Results
Of 103 patients included, 43 (42%) were diagnosed with pSjD and 40 (39%) fulfilled the 2016 ACR/EULAR classification criteria. Thirty-two (31%) had a positive minor salivary gland biopsy. The sensitivity of SGUS score ≥ 2 in at least 1 gland was 0.59 and the specificity 0.75. The positive predictive and negative predictive values were 0.51 and 0.80, respectively. The agreement slightly improved when combined with an abnormal salivary flow rate or abnormal Schirmer’s test.
Conclusion
In patients with suspected pSjD, we found good agreement between the OMERACT SGUS scoring system and minor salivary gland biopsy; however, SGUS cannot yet fully replace biopsy in the diagnostic setup of SjD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet, Copenhagen, Denmark. nanna.s.schmidt@gmail.com.
- Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Förderung
- National Hospital
Zitieren
APA
Schmidt, N. S., Fana, V., Georgiadis, S., Døhn, U. M., & Terslev, L. (2025). The agreement of the OMERACT grey-scale ultrasound scoring system for salivary glands and minor salivary gland biopsy results in a single-center cohort of patients with suspected Sjögren’s disease. Skeletal Radiology. https://doi.org/10.1007/s00256-025-04885-7
Vancouver
Schmidt NS, Fana V, Georgiadis S, Døhn UM, Terslev L. The agreement of the OMERACT grey-scale ultrasound scoring system for salivary glands and minor salivary gland biopsy results in a single-center cohort of patients with suspected Sjögren’s disease. Skeletal Radiology. 2025. doi:10.1007/s00256-025-04885-7
BibTeX
@article{Schmidt2025,
author = {Schmidt, Nanna Surlemont and Fana, Viktoria and Georgiadis, Stylianos and Døhn, Uffe Møller and Terslev, Lene},
title = {The agreement of the OMERACT grey-scale ultrasound scoring system for salivary glands and minor salivary gland biopsy results in a single-center cohort of patients with suspected Sjögren’s disease},
journal = {Skeletal Radiology},
year = {2025},
doi = {10.1007/s00256-025-04885-7}
}
EUVIMED